Brian Garibaldi, MD
Pulmonary Disease · Chicago, ILNPI 1760538979
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $352,744 of the $355,981 with a category attached, or 99.1%. Janssen Research & Development, LLC accounts for 89.4% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $171,185 and has fallen 89.1% since, to $18,602 in 2024. Among pulmonary disease clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 55 payments — averaging $6472.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$318K
- Gilead$37K
- Eko Health, Inc.$598
- AstraZeneca$118
What the payments were for
- Consulting fees$352,74499%
- Speaking & faculty fees$2,0001%
- Travel & lodging$3660%
- Food & beverage$2730%
- Charitable contribution$5980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 31 | $318,369 |
| Gilead | 22 | $36,897 |
| Eko Health, Inc. | 1 | $598 |
| AstraZeneca | 1 | $118 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$355,981 in reported general payments places this provider in the 95th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Chicago
- Douglas HogarthChicago$2.9M
- Steven WhiteChicago$970K
- Momen WahidiChicago$779K
- Septimiu MurguChicago$633K
- Ayodeji AdegunsoyeChicago$561K
- Ravi KalhanChicago$375K
- Manu JainChicago$187K
- Richard WunderinkChicago$178K
- Rade TomicChicago$70K
- Ajay WaghChicago$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.